SLC7A5 and cancer: In this regard, we would like to emphasize that the expected cancer‐specific cytostatic anti‐proliferative effects of LAT1 inhibitors,11, 26 when used with gemcitabine, may pave the way to mitigate the adverse effects and resistance caused by genotoxicity and cytotoxicity of gemcitabine.